These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 26407365)

  • 21. Guillain-Barré syndrome after vaccination in United States: data from the Centers for Disease Control and Prevention/Food and Drug Administration Vaccine Adverse Event Reporting System (1990-2005).
    Souayah N; Nasar A; Suri MF; Qureshi AI
    J Clin Neuromuscul Dis; 2009 Sep; 11(1):1-6. PubMed ID: 19730016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring.
    Vellozzi C; Burwen DR; Dobardzic A; Ball R; Walton K; Haber P
    Vaccine; 2009 Mar; 27(15):2114-20. PubMed ID: 19356614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial.
    Piedra PA; Gaglani MJ; Riggs M; Herschler G; Fewlass C; Watts M; Kozinetz C; Hessel C; Glezen WP
    Pediatrics; 2005 Sep; 116(3):e397-407. PubMed ID: 16140685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Haut Conseil de la santé publique (HCSP). Guidance on the live attenuated seasonal influenza vaccine FluenzTetra® (July 10, 2014)].
    Haut Conseil de la santé publique
    Rev Mal Respir; 2014 Oct; 31(8):773-8. PubMed ID: 25391513
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.
    Fleming DM; Crovari P; Wahn U; Klemola T; Schlesinger Y; Langussis A; Øymar K; Garcia ML; Krygier A; Costa H; Heininger U; Pregaldien JL; Cheng SM; Skinner J; Razmpour A; Saville M; Gruber WC; Forrest B;
    Pediatr Infect Dis J; 2006 Oct; 25(10):860-9. PubMed ID: 17006278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Live attenuated intranasal influenza vaccine.
    Esposito S; Montinaro V; Groppali E; Tenconi R; Semino M; Principi N
    Hum Vaccin Immunother; 2012 Jan; 8(1):76-80. PubMed ID: 22251995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in adults 18-49 years of age.
    Baxter R; Toback SL; Sifakis F; Hansen J; Bartlett J; Aukes L; Lewis N; Wu X; Ambrose CS
    Vaccine; 2012 Apr; 30(20):3053-60. PubMed ID: 22425787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Importance of influenza in the child. Intranasal influenza vaccine: another systematic vaccination?].
    Moraga Llop FA; Campins Martí M
    An Esp Pediatr; 2000 Oct; 53(4):299-304. PubMed ID: 11523509
    [No Abstract]   [Full Text] [Related]  

  • 29. Adverse Events Following Trivalent Inactivated Influenza Vaccination in Children: Analysis of the Vaccine Adverse Event Reporting System.
    Muhammad R; Haber P; Broder K; Leroy Z; Ball R; Braun MM; Davis RL; McMahon AW
    Pediatr Infect Dis J; 2011 Jan; 30(1):e1-8. PubMed ID: 21042229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surveillance for adverse events following receipt of pandemic 2009 H1N1 vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009-2010.
    Yih WK; Lee GM; Lieu TA; Ball R; Kulldorff M; Rett M; Wahl PM; McMahill-Walraven CN; Platt R; Salmon DA
    Am J Epidemiol; 2012 Jun; 175(11):1120-8. PubMed ID: 22582207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004.
    Halloran ME; Piedra PA; Longini IM; Gaglani MJ; Schmotzer B; Fewlass C; Herschler GB; Glezen WP
    Vaccine; 2007 May; 25(20):4038-45. PubMed ID: 17395338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination.
    Ambrose CS; Wu X; Belshe RB
    Pediatr Infect Dis J; 2010 Sep; 29(9):806-11. PubMed ID: 20458256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 5 through 17 years of age.
    Baxter R; Toback SL; Sifakis F; Hansen J; Bartlett J; Aukes L; Lewis N; Wu X; Ambrose CS
    Vaccine; 2012 Apr; 30(19):2989-98. PubMed ID: 22386746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of the live attenuated and the inactivated influenza vaccine in two-year-olds - a nationwide cohort study Finland, influenza season 2015/16.
    Nohynek H; Baum U; Syrjänen R; Ikonen N; Sundman J; Jokinen J
    Euro Surveill; 2016 Sep; 21(38):. PubMed ID: 27684447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children 2-17 years of age in 2013-2014 in the United States.
    Caspard H; Gaglani M; Clipper L; Belongia EA; McLean HQ; Griffin MR; Talbot HK; Poehling KA; Peters TR; Veney N; Ambrose CS
    Vaccine; 2016 Jan; 34(1):77-82. PubMed ID: 26589519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age.
    Mallory RM; Yi T; Ambrose CS
    Vaccine; 2011 Jun; 29(26):4322-7. PubMed ID: 21513761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy of live attenuated influenza vaccine against influenza-associated acute otitis media in children.
    Block SL; Heikkinen T; Toback SL; Zheng W; Ambrose CS
    Pediatr Infect Dis J; 2011 Mar; 30(3):203-7. PubMed ID: 20935591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Every nose counts: a new influenza vaccine for all healthy schoolchildren?
    Gaglani MJ; Herschler GB
    Clin Pediatr (Phila); 2004; 43(1):35-41. PubMed ID: 14968891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and tolerability of cold-adapted influenza vaccine, trivalent, in infants younger than 6 months of age.
    Vesikari T; Karvonen A; Smith HM; Dunning A; Razmpour A; Saville MK; Gruber WC; Forrest BD
    Pediatrics; 2008 Mar; 121(3):e568-73. PubMed ID: 18299305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.